Alaron Tablet, Oral Suspension
Alaron is a non-sedating antihistamine. It works by selectively binding to peripheral histamine H1-receptors on effector cells.
Alaron provides faster relief from the symptoms of hay fever, allergic rhinitis such as sneezing, nasal discharge, itching, ocular itching and burning, nasal and ocular sign and symptoms are relieved rapidly after oral administration.
Alaron is also effective in idiopathic chronic urticaria. In children over 2 years, Alaron is used for the symptomatic relief of seasonal allergic rhinitis and allergic skin conditions such as urticaria nettle rash.
Alaron is also used to associated treatment for these conditions: Allergic Dermatologic Disorders, Allergic Rhinitis (AR), Allergies, Chronic Urticaria, Common Cold, Eye pruritus, Fever, Nasal Congestion, Nasal Itching, Pain, Perennial Allergic Rhinitis (PAR), Perennial Rhinitis, Pollen Allergy, Pruritus, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Sensation of burning in the eyes, Watery eyes, Watery itchy eyes
|Loratadine Other Names||Loratadina, Loratadine, Loratadinum|
|Type||Tablet, Oral Suspension|
97 - 99% of the loratadine is bound to plasma proteins.
|Therapeutic Class||Non-sedating antihistamines|
|Last Updated:||June 23, 2021 at 11:22 am|
Adult & children over 12 years of age: One Alaron 10 mg tablet once daily (usually in the morning).
- 2-12 years (body weight more than 30 Kg): 10 mg Alaron once daily.
- 2-12 years (body weight less than 30 Kg): 5 mg Alaron once daily.
- Below 2 years of age: Safety and efficacy of Alaron have not been established.
Liver & renal impairment: Patients with liver impairment and renal insufficiency (GFR <30 ml/min) should be given a lower initial dose (10 mg every other day).
Fatigue, nausea and headache were reported rarely. Scientific studies showed that Alaron does not cause drowsiness. It does not affect performance and ability to drive or tasks requiring concentration.
Patients with liver impairment and renal insufficiency (GFR <30 ml/min) should be given a lower initial dose (10 mg every other day).
When administered concurrently with alcohol, Alaron has no potentiating effect as measured by psychomotor performance studies. Interactions with other drugs have not been reported.
Food InteractionNo interactions found.
Volume of Distribution
The volume of distribution of loratadine is 120 L/Kg.
The elimination half life is approximately 10 hours for loratadine and 20 hours for descarboethoxyloratadine.
The clearance of loratadine after single oral doses of 20 mg and 40 mg are 12 L/h/kg and 9 L/h/kg respectively. P-glycoprotein is involved in the clearance of many 2nd generation antihistamines, including loratadine, from the central nervous system. 1st generation antihistamines are not cleared by P-glycoprotein, which may help explain why they have a different central nervous system adverse effect profile compared to their 2nd generation counterparts. It appears that an antihistamine with higher affinity for p-glycoprotein will have a lower incidence of CNS adverse effects.
Pregnancy & Breastfeeding use
Use in pregnancy: There is no experience of the use of Alaron in human pregnancy, hence it should not be used during pregnancy.
Use in lactation: Alaron is excreted in breast milk, so it should not be administered to lactating mother.
Alaron is contraindicated in patients who have shown hypersensitivity or idiosyncracy to their components.
Symptoms: Somnolence, tachycardia headache, drowsiness, extrapyramidal manifestations and palpitations.
Management: Symptomatic and supportive treatment. Immediately empty stomach by inducing emesis with ipecac syrup. Admin of activated charcoal after emesis may be useful. If induction of vomiting is unsuccessful or contraindicated (e.g. patient is comatose, having seizures or lacks gag reflex), gastric lavage with NaCl 0.9% soln may be performed to prevent aspiration of gastric contents. Saline cathartics may be useful to rapidly dilute bowel contents.
Store between 20-25° C.